Spots Global Cancer Trial Database for dli
Every month we try and update this database with for dli cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | NCT02017457 | Acute Myelogeno... Myelodysplastic... | Donor lymphocyt... Azacytidine | 18 Years - | University Hospital of Mont-Godinne | |
| Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells | NCT03236129 | Hematological M... Regulatory T Ce... Relapse | T-reg depleted ... Standard DLI | - | Assistance Publique - Hôpitaux de Paris | |
| Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant | NCT03413800 | Relapsed Hemato... Multiple Myelom... | Lenalidomide-De... | 18 Years - 65 Years | Ciusss de L'Est de l'Île de Montréal | |
| Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation | NCT04886206 | Acute Myeloid L... | DLI | 18 Years - | Nantes University Hospital | |
| Adoptive Transfer of Haplo-identical DLI for AML and MDS | NCT02046122 | Acute Myeloid L... Myelodysplastic... | Idarubicin Cytarabine DLI | 55 Years - | Duke University | |
| Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL | NCT03751709 | B-Cell Acute Ly... ALL, Adult B-ALL | Blinatumomab Haplo-Mismatche... | 18 Years - | Cedars-Sinai Medical Center | |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | NCT01875237 | Leukemia Myeloma Myeloproliferat... | Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT | NCT03662087 | Minimal Residua... | HMA+DLI DLI | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion | NCT06180499 | Hematological M... Regulatory T Ce... Relapse | T-reg depleted ... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant | NCT00476177 | Hematologic Mal... | Infusion of don... Infusion of don... | 18 Years - | Dana-Farber Cancer Institute | |
| Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells | NCT03236129 | Hematological M... Regulatory T Ce... Relapse | T-reg depleted ... Standard DLI | - | Assistance Publique - Hôpitaux de Paris | |
| Adoptive Transfer of Haplo-identical DLI for AML and MDS | NCT02046122 | Acute Myeloid L... Myelodysplastic... | Idarubicin Cytarabine DLI | 55 Years - | Duke University | |
| HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT | NCT03662087 | Minimal Residua... | HMA+DLI DLI | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation | NCT02328885 | Leukemia | DLI of the 20 f... | - 60 Years | Banc de Sang i Teixits | |
| Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002). | NCT04687982 | Bone Marrow Tra... Bone Marrow Tra... Graft Vs Host D... Infection Hematological M... | modified donor ... | 18 Years - | Istituto Clinico Humanitas | |
| VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome | NCT01541280 | Acute Myeloid L... Myelodysplastic... | Azacitidine DLI | 18 Years - 70 Years | Nantes University Hospital | |
| Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT | NCT02472691 | Leukemia, Myelo... Myelodysplastic... Leukemia, Myelo... | Lenalidomide Azacitidine Donor Lymphocyt... | 18 Years - 99 Years | Heinrich-Heine University, Duesseldorf | |
| Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood | NCT01497184 | Leukemia Lymphoma | HSCT DLI | 1 Year - 65 Years | M.D. Anderson Cancer Center | |
| Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies | NCT00675831 | Hematologic Mal... | CliniMACS CD25 ... | 18 Years - | Dana-Farber Cancer Institute | |
| Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation | NCT04886206 | Acute Myeloid L... | DLI | 18 Years - | Nantes University Hospital | |
| VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome | NCT01541280 | Acute Myeloid L... Myelodysplastic... | Azacitidine DLI | 18 Years - 70 Years | Nantes University Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
